Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL148754 | 0.86 | PDCD1 (0.45) | GABRA1GABRB2CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL320050 | 0.86 | GABRA1 (0.56) | GABRA1GABRB2GABRG2GABRB3PDCD1 | |
| SCHEMBL169506 | 0.84 | GABRA1 (0.48) | GABRA1GABRB2CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL3258673 | 0.84 | GABRA1 (0.48) | GABRA1GABRB2CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL11312776 | 0.83 | GABRA1 (0.45) | GABRA1GABRB2CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL13180248 | 0.83 | GABRA1 (0.43) | GABRA1GABRB2CYP1A2PTGS2GABRG2 | |
| SCHEMBL17417172 | 0.82 | GABRA1 (0.52) | GABRA1GABRB2GABRG2GABRB3PDCD1 | |
| SCHEMBL15122404 | 0.82 | GABRA1 (0.46) | GABRA1GABRB2CYP3A4CYP1A2CYP2D6 | |
| Ammonia Solution, Strong SCHEMBL7055042 | 0.82 | GABRA1 (0.46) | GABRA1GABRB2CYP3A4CYP1A2CYP2D6 | |
| Methylamine SCHEMBL27931104 | 0.82 | GABRA1 (0.46) | GABRA1GABRB2CYP3A4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255358-A1 | Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases | GLAXO GROUP LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| US-20080255358-A1 | Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases | GLAXO GROUP LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| US-20080255358-A1 | Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases | GLAXO GROUP LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| EP-1861095-A1 | DERIVATIVES OF IMIDAZO(1,2-A)PYRIDINE USEFUL AS MEDICAMENTS FOR TREATING GASTROINTESTINAL DISEASES | GLAXO GROUP LIMITED (GB) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006100119-A1 | DERIVATIVES OF IMIDAZO (1,2-A) PYRIDINE USEFUL AS MEDICAMENTS FOR TREATING GASTROINTESTINAL DISEASES | GLAXO GROUP LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
| EP-0906288-B1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2002-11-06 | — | — | EP | disclosed |
| US-6465505-B1 | SUCH AS 4-(2,6-DIMETHYLBENZYLAMINO OR BENZYLOXY)-2-METHYL BENZIMIDAZOLE; INHIBITING EXOGENOUS OR ENDOGENOUS STIMULATED GASTRIC ACID SECRETION; PREVENTION AND TREATMENT OF GASTRO-INTESTINAL INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2002-10-15 | — | — | US | disclosed |
| EP-0971920-B1 | COMPOUNDS FOR INHIBITION OF GASTRIC ACID SECRETION | ASTRAZENECA AB (SE) | 2002-06-05 | — | — | EP | disclosed |
| US-6265415-B1 | ANTIULCER AGENT | ASTRAZENECA AB (SE) | 2001-07-24 | — | — | US | disclosed |
| EP-0971920-A1 | COMPOUNDS FOR INHIBITION OF GASTRIC ACID SECRETION | Astra Aktiebolag (SE) | 2000-01-19 | — | — | EP | disclosed |
| EP-0906288-A1 | NEW COMPOUNDS | Astra Aktiebolag (SE) | 1999-04-07 | — | — | EP | disclosed |
| WO-1998037080-A1 | COMPOUNDS FOR INHIBITION OF GASTRIC ACID SECRETION | ASTRA AKTIEBOLAG (SE) | 1998-08-27 | — | — | WO | disclosed |
| WO-1997047603-A1 | NEW COMPOUNDS | ASTRA AKTIEBOLAG (SE) | 1997-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255358-A1 | Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases | ALPI, PYGL, PPIP5K2 | GABRA1 2030/4885GABRB2 2046/4885CYP3A4 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.